Progression-Free Survival is a Suboptimal Predictor for Overall Survival Among Metastatic Solid Tumor Clinical Trials

BACKGROUND: The use of overall survival (OS) as the gold standard primary endpoint (PEP) in metastatic oncologic randomized controlled trials (RCTs) has declined in favor of progression-free survival (PFS) without a complete understanding of the degree to which PFS reliably predicts for OS. METHODS:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Cancer
Main Authors: Pasalic, Dario, McGinnis, Gwendolyn J., Fuller, C. David, Grossberg, Aaron J., Verma, Vivek, Mainwaring, Walker, Miller, Austin B., Lin, Timothy A., Jethanandani, Amit, Espinoza, Andres F., Diefenhardt, Markus, Das, Prajnan, Subbiah, Vivek, Subbiah, Ishwaria M., Jagsi, Reshma, Garden, Adam S., Fokas, Emmanouil, Rödel, Claus, Thomas, Charles R., Minsky, Bruce D., Ludmir, Ethan B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7702022/
https://ncbi.nlm.nih.gov/pubmed/32702645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2020.06.015
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados